Anima Biotech, Takeda Team Up to Develop Small Molecule Treatments

Anima Biotech, Takeda Team Up to Develop Small Molecule Treatments

291220

Anima Biotech, Takeda Team Up to Develop Small Molecule Treatments

Anima Biotech has partnered with Takeda Pharmaceuticals to develop small molecules that control mRNA translation — the process by which the information encoded in a person’s DNA is “translated” into a protein — as potential therapies for neurological disorders with a genetic cause, including Huntington’s disease. Huntington’s is caused by an expansion of three nucleotides — the building blocks of DNA, in this case the nucleotides CAG — in the huntingtin (HTT) gene. While healthy…

You must be logged in to read/download the full post.